HSBC Holdings’s Tvardi Therapeutics TVRD Stock Holding History

HSBC Holdings’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-358	Closed	-$196K	–	3189
2020 Q4	$196K	Buy	+358	New	+$188K	﹤0.01%	2829
2020 Q3	–	Sell	-397	Closed	-$244K	–	2890
2020 Q2	$244K	Buy	+397	New	+$219K	﹤0.01%	2238

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

HSBC Holdings's TVRD Position: Q1 2021 in Review

HSBC Holdings sold out of Tvardi Therapeutics (TVRD) in Q1 2021, closing a stake of 358 shares — an estimated $196K sold.

HSBC Holdings first reported a position in TVRD in Q2 2020 and held it in 2 quarters. The position peaked at $244K in Q2 2020. 168 funds tracked by Wall St. Rank hold TVRD as of Q1 2021.

HSBC Holdings reported no remaining Tvardi Therapeutics position as of Q1 2021 after selling out during the quarter.
HSBC Holdings sold 358 Tvardi Therapeutics shares in Q1 2021, an estimated $196K.
HSBC Holdings first reported a position in Tvardi Therapeutics in Q2 2020 and held it in 2 quarters.
HSBC Holdings's Tvardi Therapeutics position peaked at $244K in Q2 2020.
168 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2021.

Based on HSBC Holdings's 13F filing for Q1 2021, filed 14 May 2021.